ERBB2 and breast cancer: Enhancer/superenhancer formation involved the seeding of BRD4, MED1, H3K27 acetylation, and p300 that was shown to regulate transcriptional adaptation to MEK or HER2 inhibition in TNBC and HER2+ breast cancer models.